Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the co… Read more
Climb Bio Inc (CLYM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.097x
Based on the latest financial reports, Climb Bio Inc (CLYM) has a cash flow conversion efficiency ratio of -0.097x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.63 Million) by net assets ($160.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Climb Bio Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Climb Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Climb Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Climb Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Genus Power Infrastructures Limited
NSE:GENUSPOWER
|
-0.083x |
|
Medical Facilities Corporation
PINK:MFCSF
|
0.126x |
|
ProKidney Corp.
NASDAQ:PROK
|
-0.084x |
|
SENCO GOLD LTD
NSE:SENCO
|
0.015x |
|
Simulations Plus Inc
NASDAQ:SLP
|
0.033x |
|
Artius II Acquisition Inc. Class A Ordinary Shares
NASDAQ:AACB
|
0.000x |
|
Algoma Central Corporation
PINK:AGMJF
|
0.063x |
|
San Juan Basin Royalty Trust
NYSE:SJT
|
-0.114x |
Annual Cash Flow Conversion Efficiency for Climb Bio Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Climb Bio Inc from 2019 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $160.47 Million | $-54.36 Million | -0.339x | -361.18% |
| 2024-12-31 | $211.88 Million | $-15.56 Million | -0.073x | +61.63% |
| 2023-12-31 | $107.60 Million | $-20.60 Million | -0.191x | +34.06% |
| 2022-12-31 | $128.72 Million | $-37.37 Million | -0.290x | -34.57% |
| 2021-12-31 | $167.20 Million | $-36.07 Million | -0.216x | +67.00% |
| 2020-12-31 | $21.57 Million | $-14.10 Million | -0.654x | -169.03% |
| 2019-12-31 | $20.61 Million | $-5.01 Million | -0.243x | -- |